Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MOF Floats New Patient Cost Scheme, Eyes Revival of Old Copay System
With Japan’s budget season approaching, the Ministry of Finance (MOF) has proposed crafting a new patient cost-sharing framework that could include reviving a drug-specific copay system once applied to outpatient prescriptions. At a November 5 meeting of the Fiscal System…
To read the full story
Related Article
- MOF Panel Submits Budget Proposal, Urges Wider CEA Use and More Frequent Re-Pricing
December 3, 2025
- Ueno Signals Openness to Multiple Approaches on OTC-Like Drug Copays
November 21, 2025
- MOF Autumn Proposals Signal a Shift from Drug Pricing to Cost-Sharing Reform
November 17, 2025
- MOF Pushes Stronger Use of CEA for Pricy Meds towards FY2026 Budget
November 11, 2025
REGULATORY
- Japan to Consider Support for Domestic Immunoglobulin Production: Minister
July 16, 2026
- Govt Set to Amend Honebuto Draft over Inflation, MFN Language
July 16, 2026
- HHS Report Puts Japan’s Drug Innovation Financing Well Behind US
July 15, 2026
- MHLW Orders Label Revisions for PPIs, Checkpoint Inhibitors
July 15, 2026
- Japan Panel to Review Brinsupri, Hyrnuo, Inlexzo, GSK’s Hep B Med on July 27
July 14, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…